top of page

Cambridge, MA based Lytica Therapeutics is trying to make antibody-drug conjugates more efficient by designing the antibody portion in a way that makes cells internalize them better

  • Oct 21, 2024
  • 1 min read

Co-Founder and CEO Rida Mourtada describes how Lytica is adding a peptidic sequence to antibodies to improve their internalization into cells, with a lead ADC program targeting folate receptor alpha.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page